<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">SOTALOL</span><br/>(so-ta'lol)<br/><span class="topboxtradename">Betapace, </span><span class="topboxtradename">Betapace AF<br/></span><b>Classifications:</b> <span class="classification">autonomic nervous system agent</span>; <span class="classification">beta-adrenergic antagonist (blocking agent, sympatholytic)</span>; <span class="classification">cardiovascular agent</span>; <span class="classification">antiarrhythmic class iii</span><br/><b>Prototype: </b>Amiodarone<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p><b> Betapace</b> 80 mg, 120 mg, 160 mg, 240 mg tablets.
      </p>
<p><b>Betapace AF</b> 80 mg, 120 mg, 160 mg tablets
      </p>
<h1><a name="action">Actions</a></h1>
<p>Has both class II and class III antiarrhythmic properties. Slows heart rate, decreases AV nodal conduction, and increases
         AV nodal refractoriness.
      </p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Produces significant reductions in both systolic and diastolic blood pressure. Antiarrhythmic properties are effective in
         controlling ventricular arrhythmias as well as atrial fibrillation/flutter.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Treatment of life-threatening ventricular arrhythmias (sustained ventricular tachycardia) and maintenance of normal sinus
         rhythm in patients with atrial fibrillation/flutter.
      </p>
<h1><a name="unlabeleduses">Unlabeled Uses</a></h1>
<p>Hypertension, angina.</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Hypersensitivity to sotalol; bronchial asthma, sinus bradycardia, sick sinus syndrome; second and third degree heart block,
         long QT syndrome, cardiogenic shock, uncontrolled CHF; chronic bronchitis, emphysema; hypokalemia 
      </p><h1><a name="precaution">Cautious Use</a></h1>
<p>CHF, electrolyte disturbances, recent MI, diabetes, sick sinus rhythm, renal impairment; pregnancy (category B); concomitant
         use of drugs which prolong the QT segment, and antiarrhythmic drugs; excessive diarrhea, or profuse sweating.
      </p>
<h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Ventricular Arrhythmias (Betapace)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initial dose of 80 mg b.i.d. or 160 mg q.d. taken prior to meals, may increase every 34 d in 40160 mg increments
               (most patients respond to 240320 mg/d in 2 or 3 divided doses, doses &gt;640 mg/d have not been studied)<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> &gt;60 mL/min: q12h; 3060 mL/min: q24h; 1030 mL/min: q3648h; <br/><span class="indicationtitle">Atrial Fibrillation/flutter (Betapace AF)</span><br/><span class="rdage">Adult:</span> <span class="rdroute">PO</span> Initial dose of 80 mg b.i.d., may increase every 34 d (max: 240 mg/d in 12 divided doses)<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> &gt;60 mL/min: q12h; 4060 mL/min: q24h; <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1><span class="adminroutetype">Oral</span><br/><ul>
<li>Give on an empty stomach 1 h before or 2 h after meals. Do not give with milk or milk products.</li>
<li>Initiate and increase doses only under close supervision, preferably in a hospital with cardiac rhythm monitoring and frequent
            assessment.
         </li>
<li>Use smallest effective dose for patients with nonallergic bronchospasms.</li>
<li>Do not discontinue drug abruptly. Gradually reduce dose over 12 wk.</li>
<li>Store at room temperature, 15°30° C (59°86° F).</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead">CV:</span> AV block, hypotension, aggravation of CHF, although the incidence of heart failure may be lower than for other beta-blockers,
      <span class="speceff-life">life-threatening ventricular arrhythmias, including polymorphous ventricular tachycardia or torsades de pointes</span>, <span class="speceff-common">bradycardia, dyspnea, chest pain, palpitation,</span> bleeding (CNS: Headache, <span class="speceff-common">fatigue, dizziness,</span> weakness, lethargy, depression, lassitude. <span class="typehead">GI:</span> Nausea, vomiting, diarrhea, dyspepsia, dry mouth. <span class="typehead">Urogenital:</span> Impotence, decreased libido. <span class="typehead">Metabolic:</span> Hyperglycemia. <span class="typehead">Special Senses:</span> Visual disturbances. <span class="typehead">Respiratory:</span> Respiratory complaints. <span class="typehead">Skin:</span> Rash. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Antagonizes the effects of <span class="classification">beta agonists</span>. <b>Amiodarone</b> may lead to symptomatic bradycardia and sinus arrest. The hypoglycemic effects of <span class="classification">oral hypoglycemic agents</span> may be potentiated. May cause resistance to <b>epinephrine</b> in anaphylactic reactions. Should be used with caution with other <span class="classification">antiarrhythmic agents</span>. <span class="typehead">Food:</span> absorption of <b>sotalol</b> may be reduced by food, especially <b>milk</b> and <span class="classification">milk products</span>. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Absorption:</span> Slowly and completely absorbed from GI tract. Negligible first-pass metabolism. Absorption of sotalol may be reduced by food,
      especially milk and milk products. <span class="typehead">Peak:</span> 23 h. <span class="typehead">Duration:</span> 24 h. <span class="typehead">Distribution:</span> Drug is hydrophilic and will enter the CSF slowly (about 10%). Crosses placental barrier. Distributed in breast milk.
      Not appreciably protein bound. <span class="typehead">Metabolism:</span> Does not undergo significant hepatic enzyme metabolism and no active metabolites have been identified. <span class="typehead">Elimination:</span> Excreted by glomerular filtration in the urine with 75% of the drug excreted unchanged within 72 h. <span class="typehead">Half-Life:</span> 718 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Monitor ECG for initial baseline and periodically thereafter (especially when doses are increased) because proarrhythmic events
            most often occur within 7 d of initiating therapy or increasing dose.
         </li>
<li>Lab test: Baseline serum electrolytes. Correct electrolyte imbalances of hypokalemia or hypomagnesemia prior to initiating
            therapy.
         </li>
<li>Monitor cardiac status carefully, including ECG, throughout therapy. Exercise special caution when sotalol is used concurrently
            with other antiarrhythmics, digoxin, or calcium channel blockers.
         </li>
<li>Monitor patients with bronchospastic disease (e.g., bronchitis, emphysema) carefully for inhibition of bronchodilation.</li>
<li>Monitor diabetics for loss of glycemic control. Beta blockage reduces the release of endogenous insulin in response to hyperglycemia
            and may blunt symptoms of acute hypoglycemia (e.g., tachycardia, BP changes).
         </li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Be aware of risk for hypotension and syncope, especially with concurrent treatment with catecholamine-depleting drugs (e.g.,
            reserpine, guanethidine).
         </li>
<li>Take radial pulse daily and report marked bradycardia (pulse below 60 or other established parameter) to physician.</li>
<li>Type 2 diabetics are at increased risk for hyperglycemia. All diabetics are at risk of possible masking of symptoms of hypoglycemia.</li>
<li>Do not abruptly discontinue drug because of the risk of exacerbation of angina, arrhythmias, and possible myocardial infarction.</li>
<li>Do not breast feed while taking this drug.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>